Tirzepatide ODT 4mg

Tirzepatide ODT 4 mg is a compounded orally disintegring formulation of tirzepatide designed as a needle-free alternative to injectable therapy. It acts as a dual incretin agonist, stimulating both GLP-1 and GIP receptors to enhance insulin secretion, reduce glucagon levels, slow gastric emptying, and significantly decrease appetite. These mechanisms support improved blood glucose control and meaningful weight loss outcomes in patients with obesity or type 2 diabetes. The 4 mg ODT dose is typically considered a mid-range or step-up dose, often following lower starting doses (such as 3 mg), depending on patient tolerance and clinical response. Unlike FDA-approved injectable versions, tirzepatide ODT is compounded and dissolves in the mouth for transmucosal absorption. However, absorption can be inconsistent, and dosing is not directly equivalent to subcutaneous injections. Because compounded tirzepatide ODT has not undergone large-scale clinical trials, its safety, efficacy, and pharmacokinetics are not as well established. Common side effects remain similar to injectable forms and include nausea, decreased appetite, constipation, and fatigue. Citation: U.S. Food and Drug Administration; National Center for Biotechnology Information